AbbVie Inc (ABBV) : Thompson Rubinstein Investment Management Inc Or reduced its stake in AbbVie Inc by 2.17% during the most recent quarter end. The investment management company now holds a total of 80,012 shares of AbbVie Inc which is valued at $5,065,560 after selling 1,771 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Oct 11, 2016.AbbVie Inc makes up approximately 1.93% of Thompson Rubinstein Investment Management Inc Or’s portfolio.
Other Hedge Funds, Including , Fisher Asset Management reduced its stake in ABBV by selling 9,352 shares or 1.35% in the most recent quarter. The Hedge Fund company now holds 684,042 shares of ABBV which is valued at $43,306,699. AbbVie Inc makes up approx 0.08% of Fisher Asset Management’s portfolio. Hefty Wealth Partners added ABBV to its portfolio by purchasing 616 company shares during the most recent quarter which is valued at $39,048. AbbVie Inc makes up approx 0.03% of Hefty Wealth Partners’s portfolio.Boltwood Capital Management reduced its stake in ABBV by selling 100 shares or 0.84% in the most recent quarter. The Hedge Fund company now holds 11,852 shares of ABBV which is valued at $751,298. AbbVie Inc makes up approx 0.60% of Boltwood Capital Management’s portfolio.Washington Trust Bank reduced its stake in ABBV by selling 135 shares or 0.25% in the most recent quarter. The Hedge Fund company now holds 54,640 shares of ABBV which is valued at $3,463,630. AbbVie Inc makes up approx 0.83% of Washington Trust Bank’s portfolio.
AbbVie Inc closed down -0.92 points or -1.45% at $62.39 with 53,08,425 shares getting traded on Tuesday. Post opening the session at $63.08, the shares hit an intraday low of $62.05 and an intraday high of $63.26 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.